Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Primary Endpoint Will be Mean Change from Baseline in CAPS-5 at Week 12, Instead of Week 4

Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

NEW YORK, Oct.  31, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on November 1, 2019.

Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

NEW YORK, Oct.  23, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,449,203 to the Company on October 22, 2019. This patent, “Tianeptine Oxalate Salts and Polymorphs,” includes claims directed to crystalline tianeptine oxalate salts, and disclosures directed to methods of using those crystalline forms and their compositions. This patent, excluding possible patent term extensions, is expected to provide Tonix with U.S. market exclusivity until December 28, 2037.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

NEW YORK, Oct.  15, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it has joined the Alliance for Biosecurity (the Alliance). The Alliance is a coalition of biopharmaceutical companies and laboratory/academic partners that promotes a strong public-private partnership to ensure medical countermeasures are available to protect public health and enhance national health security. The Alliance advocates for public policies and funding to support the rapid development, production, stockpiling, and distribution of critically needed medical countermeasures.

Tonix Pharmaceuticals Joins the Alliance for Biosecurity

First-in-Class Biologic for the Treatment of Gastric and Pancreatic Cancers First-in-Class Biologic for the Treatment of Gastric and Pancreatic Cancers

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

NEW YORK, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of a paper entitled “D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD effects in rats” in the European Journal of Pharmacology. The paper summarizes the behavioral pharmacological characterization of a novel triple reuptake inhibitor (TRI), TNX-1600, formerly known as D-578, which exhibits nanomolar potency at all three monoamine transporters (NET > SERT ≈ DAT) and exhibited little to no affinity for other off-target central nervous system (CNS) receptors. TNX-1600 was found to have greater efficacy in normalizing traumatic stress-induced extinction-retention learning in an animal model for posttraumatic stress disorder (PTSD) compared to paroxetine, a selective serotonin reuptake inhibitor (SSRI), which is approved by the U.S. Food and Drug Administration (FDA) to treat PTSD and other psychiatric conditions. These findings suggest TNX-1600 may reduce maladaptive retention of fearful memories via attenuation of the extinction learning and extinction retention deficits induced by traumatic stress, supporting further testing of this agent for the pharmacotherapy of PTSD. Additionally, TNX-1600 showed a robust effect in an animal model associated with antidepressant activity without affecting locomotor activity.

Tonix Pharmaceuticals Announces Publication of Paper on Triple Reuptake Inhibitor TNX-1600 (formerly D-578) in the European Journal of Pharmacology

NEW YORK, Sept.  12, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will speak at the 2019 annual National Association of Veterans’ Research and Education Foundations’ (NAVREF) Conference being held September 15-18, 2019, in San Antonio, Texas. Tonix is a Silver Sponsor of this event.

Tonix Pharmaceuticals to Speak at the 2019 Annual National Association of Veterans’ Research and Education Foundations (NAVREF) Conference

NEW YORK, Sept.  10, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at three upcoming investor conferences.

Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

NEW YORK, Sept.  04, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that participants were dosed in a Phase 1 study evaluating the safety, tolerability and pharmacokinetics (PK) of TNX-601 (tianeptine oxalate) for the daytime treatment of posttraumatic stress disorder (PTSD). Topline data from this study investigating new modified release formulations are expected later this year.

Tonix Pharmaceuticals Doses Participants in Phase 1 Study Evaluating TNX-601 for the Daytime Treatment of Posttraumatic Stress Disorder

NEW YORK, Aug.  21, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody (mAb) that targets CD154 for the prevention and treatment of organ transplant rejection.  TNX-1500 is another step in the strategic broadening of Tonix’s portfolio of high-value programs, whose risk is mitigated by previous clinical data and extensive preclinical science.  Although transplantation is the first targeted indication for TNX-1500, it is also a potential treatment for autoimmune conditions including systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis.

Tonix Pharmaceuticals and Massachusetts General Hospital Enter into Research Collaboration to Develop Tonix’s Third Generation Anti-CD154 Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Organ Transplant Rejection

NEW YORK, Aug.  20, 2019  (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today an exclusive agreement to in-license a triple reuptake inhibitor (TRI), TNX-1600 (formerly D-578), to treat posttraumatic stress disorder (PTSD) and potentially other central nervous system (CNS) disorders. The compound was developed and pharmacologically characterized by Aloke Dutta, Ph.D., professor of Pharmaceutical Sciences at Wayne State University, with funding from a National Institutes of Health grant (grant number MH084888), and the patents covering the compounds were licensed to TRImaran Pharma, Inc. (TRImaran). The transaction announced today is a license agreement with Wayne State and an asset acquisition with TRImaran.

Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD

Tonix Pharmaceuticals Holding Corp. shares jumped sharply on Thursday after the firm announced that it has in-licensed a Phase 2 asset, TNX-1300 for the treatment of cocaine intoxication.

How Tonix Pharma Is Kicking Cocaine

Tonix Pharmaceuticals Holding Corp. disclosed Friday that the U.S. Army Medical Material Development Activity (USAMMDA) is exercising its right to "terminate without cause" the research and development agreement with the company.

Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause'

Tonix Pharmaceuticals Holding Corp. shares jumped on Monday after the firm announced the expansion of its late-stage post-traumatic stress disorder (PTSD) treatment.

PTSD Treatment Looked at for Fibromyalgia

Tonix Pharmaceuticals Holding Corp shares are gaining momentum following a Thursday morning announcement from the company.

What's Driving The Rally In Nanocap Biotech Tonix Pharma?

After Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that it is beginning to enroll patients in its late-stage study of Tonmya for the treatment of post-traumatic stress disorder (PTSD), its shares made a solid gain on Monday.

Why Investors Are Hyped for Tonix Pharma’s PTSD Late-Stage Trial

News for Tonix Pharmaceuticals Hld Stock (TNXP)